This review demonstrates the diagnosis of nephrotoxic monoclonal immunoglobulin in patients and highlights treatment strategies.
Monoclonal gammopathy of renal significance (MGRS) is a clonal lymphoproliferative disease producing nephrotoxic monoclonal immunoglobulin without meeting the criteria for lymphoproliferative syndromes or multiple myeloma. This concept has been introduced in 2012 by the International Kidney and Monoclonal Gammopathy Research Group (IKMG). The diagnosis and classification of MGRS-associated renal lesions proposed by the IKMG in 2017 is based on identification of monoclonal deposits by light microscopy and immunofluorescence studies in kidney biopsy. Hematological screening is necessary to identify the lymphoproliferative clone and treatment should target the pathologic clone responsible for the nephrotoxic monoclonal gammopathy production.Received: September 23st, 2024Accepted: April 22nd, 2025 https://dx.doi.org/10.4314/aamed.v18i3.21
No takes yet. Share an insight, caveat, or question.
Hassani et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: